Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
Shikhar Sharma(Pfizer (United States)), Meghan Hattarki(Commonwealth Scientific and Industrial Research Organisation), Paul Richardson(Pfizer (United States)), François Vaillant(The University of Melbourne), Dharmesh D. Bhuva(The University of Melbourne), Eric C. Greenwald(Pfizer (United States)), Yong Zhang(Shanghai East Hospital), Amanda J. Rickard(Monash Institute of Medical Research), Nataliya Nady(Broad Institute), Havva Pehlivanoglu(Australian Regenerative Medicine Institute), Chi‐Yeh Chung(Salk Institute for Biological Studies), Catalina Carrasco‐Pozo(University of Talca), Anderly C. Chüeh(Austin Health), Mark Devlin(The University of Melbourne), John D. Lapek(University of Rochester Medicine), Patrick Bingham(Pfizer (United States)), James R. Whittle(Walter and Eliza Hall Institute of Medical Research), Shinji Yamazaki, Showkhin Khan(Pfizer (United States)), Pei‐Pei Kung(Pfizer (United States)), S.E. Greasley(University of British Columbia), Joseph Cursons(AgriBio), Bin Ren(Commonwealth Scientific and Industrial Research Organisation), Janet Newman(Freedom to Live), Lei Chen(Shanghai Third People's Hospital), Karen L. White(Monash University), Oleg Brodsky(Pfizer (United States)), Elizabeth Allan(The University of Melbourne), Anthony N. Cuzzupe, Karen A. Maegley(Pfizer (United States)), Elliot Surgenor(Walter and Eliza Hall Institute of Medical Research), Hendrik Falk(Commonwealth Scientific and Industrial Research Organisation), Rhys Jones(Pfizer (United States)), Sean Uryu(Pfizer (United States)), Benjamin J. Morrow(Monash University), Chin Wee Tan(The University of Queensland), Alexandra E. Stupple(Monash University), Eric F. Johnson(Pfizer (United States)), Matthew L. Dennis(Commonwealth Scientific and Industrial Research Organisation), Hui Wang(Nanjing Medical University), Zhenxiong Wang(Pfizer (United States)), Jelena Petrovic(Cancer Research Institute), Scott C. Sutton(Pfizer (United States)), Anthony Mazurek(GlaxoSmithKline (United States)), Hieu Lam(Pfizer (United States)), Judy P. Doherty(The University of Melbourne), Aileen Kamal(Walter and Eliza Hall Institute of Medical Research), Konstantinos Tsaparikos(Pfizer (United States)), Joan Cao(Pfizer (United States)), Laura MacPherson(Natural Resources Canada)
Cited by 72
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
Identifying ChIP-seq enrichment using MACS
|Nature Protocols|2012|2.1k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k